Who is sponsoring NCT05483075?

NCT05483075 is sponsored by NYU Langone Health.

What drugs are being tested in NCT05483075?

Interventions in NCT05483075: HCP-Guided Exercise Training Program.

What condition does NCT05483075 study?

NCT05483075 studies Pancreatic Cancer.

Is NCT05483075 still recruiting?

NCT05483075 is currently completed. Last updated 2 May 2025.

Last reviewed 2025-05-02 · How we verify

NCT05483075

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

Completed NA Last updated 2 May 2025

What this trial tests

NA trial testing HCP-Guided Exercise Training Program in Pancreatic Cancer in 16 participants. Completed in 14 August 2024.

Timeline

15 November 2022

Primary endpoint
13 August 2024

14 August 2024

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	16
Start date	15 November 2022
Primary completion	13 August 2024
Estimated completion	14 August 2024
Sites	1 location across United States

Drugs / interventions tested

HCP-Guided Exercise Training Program

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 90, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Exercise and Nutrition Interventions for Prehabilitation in Hepato-Pancreato-Biliary Cancers: A Narrative Review.
Christopher CN, Kang DW, Wilson RL, Gonzalo-Encabo P, et al · · 2023 · cited 13× · PMID 38140303 · DOI 10.3390/nu15245044
Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma (Review).
Li H, Liu D, Li K, Wang Y, et al · · 2024 · cited 3× · PMID 38994764 · DOI 10.3892/mmr.2024.13283

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing